Research Institute, Human and Animal Bridge Discussion Group (HAB, Chiba, Japan). Human liver samples were legally procured from National Disease Research Interchange (NDRI, Pennsylvania, U.S.A.) through the international partnership between NDRI and HAB. The study was conducted in accordance with the Declaration of Helsinki. Human livers were homogenized with 0.25 M sucrose containing 3 mM Tris and 0.1 mM EDTA (pH 7.4), and microsomes were isolated by differential centrifugation using an ordinary method. Washed microsomes were resuspended in 100 mM Tris-HCl buffer (pH 7.4) containing 1 mM EDTA and 20% glycerol at protein concentrations of 20 mg/ml in the livers.
Determination of Human CYP Activities 7-Ethoxyresorufin O-deethylase activity by CYP1A1/2, coumarin 7-hydroxylase activity by CYP2A6, 7-benzyloxyresorufin Odebenzylase activity by CYP2B6, tolbutamide methylhydroxylase activity by CYP2C8/9, S-mephenytoin 4-hydroxylase activity by CYP2C19, bufuralol 1Ј-hydroxylase activity by CYP2D6, chlorzoxazone 6-hydroxylase activity by CYP2E1, and testosterone 6b-hydroxylase activity by CYP3A4 were determined as described.
11)
Standard incubation mixtures of 0.5 ml contained microsomal protein (0.1-0.5 mg), 0.1 M potassium phosphate buffer (pH 7.4), 0.1 mM EDTA, NADPH generating system (2.5 mM b-NADP, 25 mM glucose-6-phosphate, 2 units of glucose-6-phosphate dehydrogenase, and 10 mM magnesium chloride), and substrates with or without buprenorphine. Buprenorphine was dissolved in dimethyl sulfoxide and organic solvent concentration was 1 (v/v) % in the reaction system. Product formation was determined using HPLC and a fluorescence spectrophotometer. Assay methods were validated in this study. Calibration curves for resorufin, 7-hydroxycoumarine, 4-hydroxytolbutamide, 4-hydroxymephenytoin, 1Ј-hydroxybufuralol, 6-hydrochlorzoxazone, and 6b-hydroxytestosterone were established with respective calibration ranges of 0.2-200 nM (gϭ0.9996), 0.025-5 mM (gϭ1.0000), 0.05-10 mM (gϭ0.9998), 0.025-5 mM (gϭ0.9996), 0.025-5 mM (gϭ0.9995), 0.25-100 mM (gϭ0.9994), and 0.03-30 mM (gϭ0.9999).
The substrate concentrations used to estimate the kinetic parameters for each assay were 0.01-10 mM 7-ethoxyresorufin, 0.1-100 mM coumarin, 0.03-10 mM 7-benzyloxyresorufin, 25-1000 mM tolbutamide, 5-500 mM S-mephenytoin, 5-200 mM bufuralol, 10-400 mM chlorzoxazone, and 10-250 mM testosterone. For the determination of the residual activity in the presence of buprenorphine (30-300 mM), the concentrations of substrates were 0.5 mM 7-ethoxyresorufin, 2 mM coumarin, 1 mM 7-benzyloxyresorufin, 100 mM tolbutamide, 100 mM S-mephenytoin, 20 mM bufuralol, 100 mM chlorzoxazone, and 100 mM testosterone. Selective CYP inhibitors were used in this study to validate that the assays were working properly. 7,8-Benzoflavone, 12) furafylline, 13) orphenadrine, 14) quercetin, 15) sulfaphenazole, 16) tranylcypromine, 17) quinidine, 18) diethyldithiocarbamate, 19) and ketoconazole, 20) which are inhibitors of CYP1A1, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4 activities, inhibited the respective enzyme activities (data not shown). Diethyldithiocarbamate is also known to be a specific inhibitor of CYP2A6 12) and the present study confirmed the potent inhibitory capability of this compound on CYP2A6 mediated metabolism (data not shown).
For the determination of the Ki values, the ranges of 7-ethoxyresorufin and buprenorphine concentrations were 0.25-1 mM and 50-150 mM, respectively; those of 7-benzyloxyresorufin and buprenorphine concentrations were 0.75-3 mM and 30-300 mM; those of S-mephenytoin and buprenorphine concentrations were 100-400 mM and 30-300 mM; those of bufuralol and buprenorphine concentrations were 20-80 mM and 10-100 mM; and those of testosterone and buprenorphine concentrations were 50-200 mM and 10-100 mM, respectively.
Data Analysis Apparent K m and V max values for the formation of metabolites were calculated by a nonlinear regression analysis using a computer program, WinNonlin Standard (Version 2.1, Scientific Consulting, Inc., Apex, NC, U.S.A.). The method of Dixon 21) was used to calculate inhibition constants (Ki).
RESULTS AND DISCUSSION
Multiple drug therapy is a common therapeutic practice, particularly for patients with various diseases. Whenever 2 or more drugs are administered concurrently, there is the possibility of drug interaction. Many drug interactions are clinically caused by inhibition of drug metabolizing enzymes, cytochrome P450s (CYPs), leading to decreased metabolic clearance and increased exposure to the inhibited drug. The inhibition of CYP enzymes should thus be examined to assess the potential for drug interactions.
The current study examined the in vitro ability of buprenorphine to inhibit the metabolism of substrates for CYP1A1/2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (Table 1 and Fig. 2 ). Buprenorphine had strong inhibitory effects on CYP3A4-mediated testosterone 6b-hydroxylation and CYP2D6-mediated bufuralol 1Ј-hydroxylation with Ki values of 14.7 mM and 21.4 mM, respectively. The type of inhibition was considered to be competitive from Dixon plots. In addition, buprenorphine had weak inhibitory effects on CYP1A1/ 2-mediated 7-ethoxyresorufin O-deethylation (Kiϭ132 mM), CYP2B6-mediated 7-benzyloxyresorufin O-debenzylation (Kiϭ133 mM), CYP2C19-mediated S-mephenytoin 4-hydroxylation (Kiϭ146 mM), CYP2C8/9-mediated tolbutamide methylhydroxylation (IC 50 Ͼ300 mM), and CYP2E1-mediated chlorzoxazone 6-hydroxylation (IC 50 Ͼ300 mM), while it did not inhibit CYP2A6-mediated coumarin 7-hydroxylation at concentrations up to 300 mM. Buprenorphine is a substrate of CYP3A4, 9, 10) and thus may have the strongest inhibitory effect on CYP3A4 catalyzed reactions.
The lowest Ki value (CYP3A4; Kiϭ14.7 mM) was used to estimate conservatively the potential for inhibitory drug interactions with buprenorphine during clinical use of the drug. Peak plasma concentration of buprenorphine after an intravenous dose of 1.2 mg, a sublingual dose of 4 mg, or a buccal dose of 4 mg in healthy volunteers was 24.40 to 55.83 ng/ml (0.0522 to 0.119 mM), 1.93 to 7.20 ng/ml (0.00413 to 0.0154 mM), and 0.25 to 3.90 ng/ml (0.000535 to 0.00834 mM), respectively. 22) Oral dose of 40 mg or subcutaneous dose of 2 mg to a patient produced peak levels of 0.57 to 4.69 ng/ml (0.00122 to 0.0100 mM) and 0.2 to 8.74 ng/ml (0.000428 to 0.0187 mM), respectively.
23) Plasma concentration of buprenor- phine is 120 times less than the apparent Ki value determined in the in vitro studies, suggesting buprenorphine to possibly have little or no inhibitory effect on the metabolism of drugs oxidized by CYP1A1/2, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 in vivo. Actually, there are no clinical reports that buprenorphine causes drug-drug interactions with other CYP-metabolized drugs.
To extrapolate in vitro inhibition data to in vivo situations, free concentrations of drug and inhibitor at the site of metabolism are important. 24, 25) However this factor is difficult to evaluate in vitro. Often in vivo and/or in vitro unbound plasma concentration of a drug and/or inhibitor is used to approximate concentrations of both at an enzyme site. Plasma protein binding of buprenorphine was determined in vitro to be Ͼ95% 26) and the drug primarily bound to a-and b-globulin fractions.
3) The free (unbound) concentration of buprenorphine may thus be approximately 0.05 times the total concentration in plasma. Lower plasma level of buprenorphine compared to the apparent Ki value and high plasma protein binding of buprenorphine indicated intracellular binding or the accumulation of buprenorphine in hepatocytes on the in vivo inhibition may not significantly affect the assessment of metabolic drug interactions made in this study.
In conclusion, the results of in vitro experiments performed with human liver microsomes indicated that, although buprenorphine inhibited CYP1A1/2, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4-mediated catalytic activity, this compound, at expected therapeutic concentrations, would not be predicted to cause clinically significant interactions with other CYP-metabolized drugs.
